.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A16A_OtherAlimentaryTractAndMetabolismProducts.A16AX19_Fosdenopterin.Fosdenopterin .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A16A_OtherAlimentaryTractAndMetabolismProducts.A16AX19_Fosdenopterin.Fosdenopterin| name: | Fosdenopterin |
| ATC code: | A16AX19 | route: | intravenous |
| n-compartments | 1 |
Fosdenopterin is a synthetic cyclic pyranopterin monophosphate surrogate indicated for the treatment of molybdenum cofactor deficiency (MoCD) type A, a rare, inherited metabolic disorder. The drug acts as a substrate replacement, compensating for the biochemical defect in MoCD type A that leads to a life-threatening accumulation of toxic metabolites. Fosdenopterin is approved for use in specific patient populations, notably pediatric and adult patients with this condition.
Pharmacokinetic estimates are based on summary prescribing information and regulatory approval documents for pediatric and adult patients with MoCD type A. Parameters are not from a published, peer-reviewed pharmacokinetic study.